Skip to content

Evaluation of Effectiveness and Safety With a Bioinductive Collagen Patch for Massive Rotator Cuff Tears

Evaluation of Effectiveness and Safety With a Bioinductive Collagen Patch for Massive Rotator Cuff Tears

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118666
Enrollment
Unknown
Registered
2026-02-09
Start date
2026-02-09
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Massive Rotator Cuff Tears

Interventions

Observation group:NA

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1 Age >= 18 years, any gender 2 Imaging criteria: tear size >= 5 cm or accompanied by separation of 2 or more tendons. 3 Persistent shoulder pain and/or limited mobility, not amenable to direct repair, failed conservative treatment (symptoms not relieved after 3 months), and willing to undergo biological induced collagen patch surgery (this treatment is a routine option for massive rotator cuff tears). 4 Assessed by a multidisciplinary team (Orthopedics, Anesthesiology, Geriatrics) as able to tolerate arthroscopic surgery and cooperate with postoperative rehabilitation plan (e.g., wearing a brace as required, attending regular follow-ups). 5 Signed informed consent and completed baseline assessment, voluntarily agreeing to participate in long-term follow-up.

Exclusion criteria

Exclusion criteria: 1 Injury-related contraindications: Traumatic rotator cuff tear (such as a confirmed history of shoulder fracture or dislocation); Presence of other severe shoulder joint lesions (such as labral tears, shoulder arthritis, shoulder instability); Previous history of shoulder surgery (including rotator cuff repair, acromioplasty, etc.). 2 General condition contraindications: Severe cardiovascular or cerebrovascular diseases (such as acute myocardial infarction =180mmHg); History of malignancy (metastatic tumors or active cancer); Severe mental illness (such as dementia, schizophrenia) or inability to comply with follow-up; Active infection (such as shoulder joint infection, systemic sepsis); Severe coagulation disorders (INR >3.0 or platelet count 0.5 or expected survival <1 year. 3 Loss to follow-up or missing data: Missing two consecutive scheduled follow-ups (phone/clinic) and cannot be contacted, or refusal to undergo further evaluation (such as imaging or functional scoring); missing American Shoulder and Elbow Surgeons (ASES) scores and imaging (MRI/ultrasound) within 12 months after treatment and unable to obtain them later. 4 Violation of study protocol: Patients failing to stop medications as required perioperatively (e.g., taking anticoagulants on their own increasing bleeding risk) or refusing postoperative rehabilitation. 5 Conditions that may affect prognosis, including autoimmune diseases, poorly controlled diabetes, pregnancy, etc. 6 Participation in other clinical studies that may affect the results of this study. 7 Patient or family explicitly requests to withdraw from the study, either in writing or orally.

Design outcomes

Primary

MeasureTime frame
American Shoulder and Elbow Surgeons (ASES) Score;

Secondary

MeasureTime frame
Visual Analog Scale (VAS) for Pain;Shoulder mobility;Imaging results;

Countries

China

Contacts

Public ContactLiu Xudong

Shanghai Sixth People's Hospital

doctorliuxd@126.com+86 136 3665 0777

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026